Liquidia (LQDA) announced that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware has set aside the injunction that was issued in August 2022
Liquidia (LQDA) announced that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware has set aside the injunction that was issued in August 2022
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV – Research Report), United Therapeutics (UTHR – Research Report) and Immunome (IMNM – Research Report) with bullish sentiments.
IQVIA Holdings (IQV)
In a report issued on March 27, Michael Cherny from Leerink Partners maintained a Buy rating on IQVIA Holdings, with a price target of $290.00. The company’s shares closed last Thursday at $252.89, close to its 52-week high of $261.73.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $277.50 average price target.
See today’s best-performing stocks on TipRanks >>
United Therapeutics (UTHR)
In a report issued on March 26, Roanna Ruiz from Leerink Partners maintained a Buy rating on United Therapeutics, with a price target of $335.00. The company’s shares closed last Thursday at $229.72.
According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $290.00 average price target, representing a 19.1% upside. In a report issued on March 26, Wells Fargo also maintained a Buy rating on the stock with a $325.00 price target.
Immunome (IMNM)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Immunome on March 26 and set a price target of $38.00. The company’s shares closed last Thursday at $24.68.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunome with a $32.50 average price target, a 27.3% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IQV:
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on United Therapeutics (UTHR – Research Report), Regeneron (REGN – Research Report) and Intuitive Surgical (ISRG – Research Report) with bullish sentiments.
United Therapeutics (UTHR)
In a report released yesterday, Tiago Fauth from Wells Fargo assigned a Buy rating to United Therapeutics, with a price target of $325.00. The company’s shares closed last Monday at $244.26.
According to TipRanks.com, Fauth has 0 stars on 0-5 stars ranking scale with an average return of
United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $289.44.
See the top stocks recommended by analysts >>
Regeneron (REGN)
In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Buy rating to Regeneron, with a price target of $1050.00. The company’s shares closed last Monday at $961.09, close to its 52-week high of $998.33.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $1036.77, an 8.7% upside from current levels. In a report issued on March 11, Bernstein also initiated coverage with a Buy rating on the stock with a $1125.00 price target.
Intuitive Surgical (ISRG)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Intuitive Surgical, with a price target of $416.00. The company’s shares closed last Monday at $391.71, close to its 52-week high of $403.00.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $414.56, implying a 5.3% upside from current levels. In a report issued on March 15, Stifel Nicolaus also maintained a Buy rating on the stock with a $420.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UTHR:
An announcement from United Therapeutics (UTHR) is now available. United Therapeutics Corporation has initiated a $1 billion buyback of its common stock, engaging in an accelerated share repurchase agreement with
United Therapeutics (UTHR) announced that its Board of Directors has authorized the company to purchase up to $1B of United Therapeutics’ common stock. This program builds on United Therapeutics’ planned